QSAM News and Press, QSAM Biosciences Inc From 09/12/22

Osteosarcoma is a rare bone cancer that most often affects the long bones in the legs and arms. Although it occurs most often in young adults, older adults and younger children are also at risk of developing osteosarcoma . This type of bone cancer is often characterized by bone pain and...

Cancer is said to be the second-leading cause of death globally, following heart disease. Among the different types of cancer, lung cancer is the leading cause of cancer death , followed by colorectal and liver cancers. A new study suggests that roughly 44% of the deaths caused by cancer ca...

QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using a nonradioactive kit that can b...

New research has found that Hodgkin’s lymphoma patients have a higher likelihood of suffering from substance-abuse and mental health disorders, in comparison to the general population. Hodgkin’s lymphoma works by attacking an individual’s immune system. The highly cura...

Around 1 in 285 children will develop some kind of cancer before they turn 20. Cancer is one of the deadliest disease that afflicts children and adolescents, taking an estimated 1,800 lives in the United States each year. Although scientists still haven’t developed a cure for canc...

This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families. “CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says QSAM CEO. Pate...

QSAM Biosciences press release ( OTCQB:QSAM ): Q2 GAAP EPS of -$0.79. As of June 30, 2022, the Company had cash of approximately $0.43 million. The Company believes this is sufficient capital to support operations at the current pace into the third quarter of 2022. ...

Progress Shown in Phase 1 Clinical Program Evaluating CycloSam ® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company de...

Cancer is the second most common cause of death in the United States, affecting nearly two million people yearly and taking more than one-half a million lives every year. Almost one-half of the people who suffer from cancer are diagnosed with the deadly condition late. More often than ...

New research has identified a molecule that is involved in both cardiovascular disease and cancer metastasis. For cancer to become malignant, cells in tumors undergo various transformations that involve interactions between the tumor and an individual’s immune system. While most o...